New combo aims to boost remission in rare lymphoma

NCT ID NCT06510309

Recruiting now Disease control Sponsor: Gottfried von Keudell, MD PhD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study is testing whether combining rituximab (an antibody) with venetoclax (a targeted pill) can improve outcomes for people with untreated marginal zone lymphoma. About 33 participants will receive the combination, and researchers will measure how many achieve a complete response. The goal is to find a more effective frontline therapy for this slow-growing blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab and venetoclax
What this could lead to: If successful, this combination could offer a more effective first-line treatment for marginal zone lymphoma, potentially leading to higher remission rates.
What could go wrong: This is a small, early-phase trial with only 33 participants. The treatment may not work better than standard options, and side effects like low blood counts or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA MARGINAL ZONE LYMPHOMA MZL

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.